A Phase 1 Open Label Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PHIN-214 in Adults with Child Pugh A and B Cirrhosis
Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PHIN-214 in Adults with Child Pugh A and B Cirrhosis
Sponsor: PharmaIN Corporation
Enrolling: Male and Female Patients
IRB Number: ACYY2024
U.S. Govt. ID: NCT05490888
Contact: Transplant Clinical Research Center: 212-305-3839 / tcrcstudyreferral@cumc.columbia.edu
Additional Study Information: Researchers at Columbia University Irving Medical Center are investigating whether PHIN-24 is safe and tolerable after single and multiple ascending doses for people with advanced cirrhosis. Advanced liver cirrhosis is the late stage of chronic liver scarring, where the liver has lost most of its ability to function normally.
This study is closed
Investigator
Giuseppe Cullaro, MD
Do You Qualify?
Are you 18 years of age and younger than 75 years of age? Yes No
Have you been diagnosed with Cirrhosis? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder


CAPTCHA
Image CAPTCHA
Enter the characters shown in the image.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Cancel
For more information, please contact:
Transplant Clinical Research Center
tcrcstudyreferral@cumc.columbia.edu
212-305-3839